Description
Our immunotherapy projects rely on a novel gene delivery system or, docking platform (DP), patented by our group. The goal of this line of work is to develop a new generation of therapies for different diseases: solid and liquid tumors, fungal infections, antibiotic-resistant bacterial infections, etc. The transfer of genes (antibodies, cytokines, checkpoint inhibitors, Chimeric Antigen Receptors (CARs), etc.) aimed at endowing cells with new therapeutic capacities is performed on immunocompatible iPS cells carrying the DP at a Genomic Safe Harbor (GSH) site of the genome. Fully equipped iPS cells are later differentiated in vitro into NK lymphocytes and macrophages. The resulting immunocompatible effector cells can then be used in allogenic transplants for all patients who need them.
The figure below shows the maintenance of the mCherry marker expression throughout the differentiation process of human iPS cells. Four copies of mCherry have been installed on the docking platform located at a GSH site.
Members
Head:
Group